📊 GEHC Key Takeaways
Is GE HealthCare Technologies Inc. (GEHC) a Good Investment?
GEHC demonstrates solid profitability with 40% gross margins and 20.1% ROE, supported by 4.8% revenue growth. However, negative free cash flow of -$138M despite $344M operating cash flow raises concerns about capital intensity and cash generation sustainability, requiring operational leverage improvements.
GE HealthCare shows solid core fundamentals with mid-single-digit revenue growth, healthy 40.0% gross margin, and double-digit operating and net margins. However, flat net income and negative free cash flow indicate weaker earnings-to-cash conversion, which tempers the quality of growth despite a manageable liquidity profile and acceptable leverage.
Why Buy GE HealthCare Technologies Inc. Stock? GEHC Key Strengths
- Strong profitability metrics with 40% gross margin and 13.4% operating margin indicating pricing power and operational efficiency
- Robust return on equity at 20.1% demonstrates effective capital deployment relative to shareholder investment
- Consistent revenue growth of 4.8% YoY in medical device sector shows market demand and competitive positioning
- Healthy profitability profile with 40.0% gross margin, 13.4% operating margin, and 10.1% net margin
- Revenue and diluted EPS both grew 4.8% year over year, indicating continued operating resilience
- Balance sheet remains serviceable with 1.37x current ratio, 1.13x quick ratio, and strong 20.1% ROE
GEHC Stock Risks: GE HealthCare Technologies Inc. Investment Risks
- Negative free cash flow of -$138M signals capital expenditure significantly exceeds operating cash generation, raising sustainability concerns
- High leverage with 0.96x debt/equity ratio and $10B long-term debt represents material financial risk relative to $10.4B equity base
- Deteriorating cash conversion despite positive net income growth suggests operational cash generation is weakening relative to profitability
- Operating cash flow of only $344M versus $2.08B net income suggests weak cash conversion
- Free cash flow was negative at -$138M, raising questions about underlying cash generation quality
- Leverage is meaningful with $10.00B long-term debt and debt-to-equity of 0.96x, limiting flexibility if cash flow stays soft
Key Metrics to Watch
- Free cash flow trend and operating cash flow sustainability to assess if capital intensity is improving
- Debt/equity ratio movement as company scales to ensure leverage remains manageable
- Operating margin expansion potential to drive cash conversion efficiency and offset capital expenditure requirements
- Operating cash flow and free cash flow recovery
- Net income growth relative to revenue growth
GE HealthCare Technologies Inc. (GEHC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
GE HealthCare Technologies Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GEHC Profit Margin, ROE & Profitability Analysis
GEHC vs Market Sector: How GE HealthCare Technologies Inc. Compares
How GE HealthCare Technologies Inc. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GE HealthCare Technologies Inc. Stock Overvalued? GEHC Valuation Analysis 2026
Based on fundamental analysis, GE HealthCare Technologies Inc. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GE HealthCare Technologies Inc. Balance Sheet: GEHC Debt, Cash & Liquidity
GEHC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GE HealthCare Technologies Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $3.03 reflects profitable operations.
GEHC Revenue Growth, EPS Growth & YoY Performance
GEHC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.9B | $446.0M | $0.98 |
| Q2 2025 | $4.8B | $428.0M | $0.93 |
| Q1 2025 | $4.7B | $374.0M | $0.81 |
| Q3 2024 | $4.8B | $375.0M | $0.82 |
| Q2 2024 | $4.8B | $418.0M | $0.91 |
| Q1 2024 | $4.7B | $372.0M | $0.41 |
| Q3 2023 | $4.6B | $375.0M | $0.82 |
| Q2 2023 | $4.5B | $418.0M | $0.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GE HealthCare Technologies Inc. Dividends, Buybacks & Capital Allocation
GEHC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GE HealthCare Technologies Inc. (CIK: 0001932393)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GEHC
What is the AI rating for GEHC?
GE HealthCare Technologies Inc. (GEHC) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GEHC's key strengths?
Claude: Strong profitability metrics with 40% gross margin and 13.4% operating margin indicating pricing power and operational efficiency. Robust return on equity at 20.1% demonstrates effective capital deployment relative to shareholder investment. ChatGPT: Healthy profitability profile with 40.0% gross margin, 13.4% operating margin, and 10.1% net margin. Revenue and diluted EPS both grew 4.8% year over year, indicating continued operating resilience.
What are the risks of investing in GEHC?
Claude: Negative free cash flow of -$138M signals capital expenditure significantly exceeds operating cash generation, raising sustainability concerns. High leverage with 0.96x debt/equity ratio and $10B long-term debt represents material financial risk relative to $10.4B equity base. ChatGPT: Operating cash flow of only $344M versus $2.08B net income suggests weak cash conversion. Free cash flow was negative at -$138M, raising questions about underlying cash generation quality.
What is GEHC's revenue and growth?
GE HealthCare Technologies Inc. reported revenue of $20.6B.
Does GEHC pay dividends?
GE HealthCare Technologies Inc. pays dividends, with $64.0M distributed to shareholders in the trailing twelve months.
Where can I find GEHC SEC filings?
Official SEC filings for GE HealthCare Technologies Inc. (CIK: 0001932393) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GEHC's EPS?
GE HealthCare Technologies Inc. has a diluted EPS of $4.55.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GEHC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GE HealthCare Technologies Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GEHC stock overvalued or undervalued?
Valuation metrics for GEHC: ROE of 20.1% (sector avg: 15%), net margin of 10.1% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy GEHC stock in 2026?
Our dual AI analysis gives GE HealthCare Technologies Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GEHC's free cash flow?
GE HealthCare Technologies Inc.'s operating cash flow is $344.0M, with capital expenditures of $482.0M. FCF margin is -0.7%.
How does GEHC compare to other Market stocks?
Vs Default sector averages: Net margin 10.1% (avg: 12%), ROE 20.1% (avg: 15%), current ratio 1.37 (avg: 1.8).